Tag Archives: OPHLF

Best Medical Stocks To Own Right Now

With Social Security funding issues around the corner, uncertain market conditions, long-term low interest rates and skyrocketing medical costs, American retirees are facing a laundry list of retirement challenges. The only certainty is that retirement is going to be dramatically different than the retirement previous generations encountered. In order to retire with financial security and dignity, Americans need to make well-informed decisions about when to retire, when to collect Social Security, how to manage their retirement savings and what to do about housing in retirement.  It is this last item, housing in retirement, which often gets the least amount of attention, when in fact, it should be closely scrutinized as a powerful asset.

New research from The American College of Financial Services, The Home Equity and Retirement Income Planning Survey, found that the overwhelming majority, 83 percent of Americans nearing or in retirement, want to remain in their current home for as long as possible. Additionally, the desire to remain in one’s home increased with age. Perhaps somewhat surprisingly, not only did the desire to remain in one’s home increase with age, but the number of years the respondent expected to remain in the home also increased with age. Even if the homeowner needed to relocate later in retirement, almost none of the respondents expressed a desire to rent. This research has also been published in the Journal of Financial Planning – see here.

Best Medical Stocks To Own Right Now: Rockwell Medical Technologies Inc.(RMTI)

Advisors’ Opinion:

  • [By Alex McGuire]

    As a service to our readers, the following list provides the 10 top pharmaceutical stocks to watch this month (May 2017), including the biggest gainers from April…

    Pharmaceutical Stock Current Share Price April 2017 Gain
    Cleveland BioLabs Inc. (Nasdaq: CBLI) $3.62 +120.6%
    Nexvet Biopharma Plc. (Nasdaq: NVET) $6.61 +69.7%
    Motif Bio Plc. (Nasdaq ADR: MTFB) $10.10 +68.2%
    Axovant Sciences Ltd. (NYSE: AXON) $24.43 +62.3%
    Cyclacel Pharmaceuticals Inc. (Nasdaq: CYCC) $5.49 +46.7%
    Conatus Pharmaceuticals Inc. (Nasdaq: CNAT) $8.67 +44.9%
    Akebia Therapeutics Inc. (Nasdaq: AKBA) $13.07 +43.3%
    Akorn Inc. (Nasdaq: AKRX) $33.28 +38.9%
    Rockwell Medical Inc. (Nasdaq: RMTI) $8.78 +37.4%
    Akari Therapeutics Plc. (Nasdaq ADR: AKTX) $15.02 +35.4%

    The best-performing pharma stock of the month – Cleveland BioLabs Inc. – surged 120.6% to $3.53 a share by April 28. That crushed both the Nasdaq Biotech Index’s 1.5% gain and the Dow Jones’ 1.3% rise over the same period.

  • [By Lisa Levin]

    Thursday morning, the healthcare sector proved to be a source of strength for the market. Leading the sector was strength from Keryx Biopharmaceuticals (NASDAQ: KERX) and Rockwell Medical Inc (NASDAQ: RMTI).

Best Medical Stocks To Own Right Now: HCI Group, Inc.(HCI)

Advisors’ Opinion:

  • [By Jim Robertson]

    Small cap Florida insurance stock HCI Group Inc (NYSE: HCI) has taken a hit with shares down around 21% over the past week on predictions that Hurricane Irma would hit Florida albeit sharesrose 2.74%on Friday when it became clear that it would not be as catastrophic as feared:

Best Medical Stocks To Own Right Now: Sonic Corp.(SONC)

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap burger stock Sonic Corporation (NASDAQ: SONC) reported fiscal Q1 2018 earnings after the market closed Thursday that exceeded Wall Street expectations. Total revenues were $105.428 million versus $129.551 million assystem same-store sales declined 1.7% – consisting of a 1.6% same-store sales decrease at franchise drive-ins and a 3.2% decrease at company drive-in. Net income totaled $11.4 million versus net income of $13.1 million. The CEO commented:

  • [By Peter Graham]

    Small cap burger stock Sonic Corporation (NASDAQ: SONC) reported fiscal Q3 2017 earnings after the market closed yesterday with earnings exceeding Wall Street expectations. GAAP revenue was $123.990 million versus $165.239 million as system same-store sales declined 1.2% consisting of a 1.1% same-store sales decrease at franchise drive-ins and a 3.2% decrease at company drive-ins. Net income totaled $18.8 million versus net income of $15.4 million. The Chairman/CEO commented:

  • [By Peter Graham]

    After the market closed yesterday, small cap burger stock Sonic Corporation (NASDAQ: SONC) reported fiscalQ2 2017 earnings with shares falling moderately in after hours trading as the top line missed and the bottom line met expectations. However, it appears analysts are zeroing in on the system same-store sales comps down 7.4% versus expectations for a fall of 4.3%. The decline was comprised of a7.3% same-store sales decline at franchise drive-ins and a decline of 8.9% at company drive-ins.

  • [By Peter Graham]

    A long term performance chart shows shares of newcomers Shake Shack and California based IPO Habit Restaurants both underperforming or below their IPO close prices whilemore established small capburger stocks Red Robin Gourmet Burgers, Inc (NASDAQ: RRGB) and Sonic Corporation (NASDAQ: SONC) were big outperformers up until more recently:

  • [By ]

    Among McDonald’s main rivals, identified by FactSet, are Starbucks Corp. (SBUX) , down almost 5.5%; Yum! Brands (YUM) , which owns KFC, Pizza Hut and Taco Bell, up 32%; and burger chain Sonic Corp. (SONC) , down about 2%. These are all year-over-year percentages.

  • [By Peter Graham]

    A long term performance chart shows shares of small caps Habit Restaurants and Shake Shack Inc (NYSE: SHAK) below their IPO prices while more established burger stocks Red Robin Gourmet Burgers, Inc (NASDAQ: RRGB) and Sonic Corporation (NASDAQ: SONC)have seen their performance drift downward last year or the year before:

Best Medical Stocks To Own Right Now: Sack Lunch Productions (SAKL)

Advisors’ Opinion:

  • [By James E. Brumley]

    Tuesday morning, Sack Lunch Productions Inc (OTCMKTS:SAKL) posted its results for the third quarter (ending September 30th) of the year. They were as strong as you might suspect, with the top line rolling in at $5.35 million, and $142,983 of that turning into net income. That top and bottom line were actually down a bit from the year-ago comparables, though investors should bear in mind that the third quarter of last year was an unusually tough comparison of $6.02 million in sales, and income of $688,845. That was a true breakout quarter for the company’s signature event – Slide the City – and many participants may have come simply to see what it was. The follow-up year (this year), SAKL may not have had the same curiosity factor compelling people to attend.

    Sack Lunch Productions, for the unfamiliar, it’s the name behind event-oriented businesses called Slide the City, Lantern Fest, The Dirty Dash, the Color Me Rad 5K run, and most recently, the Trike Riot. Those are a 1000-foot Slip-n-Slide, a flying lantern release, a mud run, a color-splashing fun run, and a tricycle riding course for kids of all ages and sizes. The events aren’t just fun – they’re FUN!

    They’re also surprisingly profitable. While attendance and per-participant revenue varies, with the average revenue of $30 per participant being at the low end of the scale ( as is the average event attendance of 2500), gross revenue of $75,000 per event is a low-end expectation…

    … not that SAKL hasn’t done some more number crunching of its own. This year, it expects to host roughly 250 events and drive $17 million worth of revenue per event, up about 80% from 2015’s top line. Some of those are being put on by Sack Lunch Productions itself, while others are being hosted by franchisees. Whatever the case, that works out to average revenue of $72,000 per event, with the franchised ones being low-cost to no-cost events for SAKL.

    Regardless, the trend is an impressive one, all

Best Medical Stocks To Own Right Now: Vitality Biopharma (VBIO)

Advisors’ Opinion:

  • [By James E. Brumley]

    Are you an investor interested in learning more about Vitality Biopharma Inc (OTCMKTS:VBIO)? Or, are you looking to take your first look at VBIO? A SeeThruEquity research report posted in August not only has you covered, it underscores all of its hidden bullishness. The report also explains a very impressive target price for Vitality Biopharma shares. In short, the research outfit now believes the stock will see $2.00 per share sooner than later, based on its pipeline and potential market penetration. That’s 38% higher than its current value.

  • [By Jim Robertson]

    That’s why its worth pointing out that just yesterday, small cap cannabinoid prodrug pharmaceutical stock Vitality Biopharma, Inc. (OTCQB: VBIO) announced the appointment of Tracy Rockney, J.D. to the position of Senior Regulatory Advisor. In addition to being the Co-Founder & Chief Operating Officer of OneSource Regulatory, a regulatory consulting firm, Rockney was previously:

  • [By James E. Brumley]

    Investors who were looking to learn a little more about up-and-coming drug development company Vitality Biopharma Inc (OTCMKTS:VBIO) may want to mark December 8th on their calendar…. if they’re going to be in the Los Angeles area that day anyway. The company will be making a presentation that day, at the annual LD Micro Main Event. Interested and approved investors can attend the VBIO presentation by registering beforehand with LD Micro.

    Vitality Biopharma has found a way to make cannabinoid-based pharmaceuticals without the usual downside of cannabinoids. Namely, Vitality Biopharma’s version of cannabinoids are non-psychotropic, meaning larger, more effective dosing is possible without the ‘high’. It’s this little detail that takes cannabinoid medicine — already the most compelling frontier in the world of pharma — to the next level. There’s a reason some people think the cannabinoid market could be worth $20 billion by 2020.

    The idea was significantly advanced in early November. In eight of the nine states voters were asked about legalization of marijuana (for one reason or another), voters said yes….. four for recreational use, and four for medical use. In eight of those nine states, the measures passed. Marijuana is legal in more than half the United States now, and we’re en route to a decided majority in the foreseeable future.

    VBIO didn’t necessarily need a sweeping victory at the ballot box, but each time marijuana wins, it seems to advance the discussion of the power of cannabinoids as medicine.

    Investors will be able to learn more about Vitality Biopharma’s work in that arena on Thursday of this week. On that day — 8 AM PST / 11 AM EST — at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Robert Brooke, CEO of Vitality Biopharma, will be making a presentation as well as meeting with current and prospective investors.

    LD Micro was founded in 2006 with the sole purpose of being an independent resource in t

  • [By James E. Brumley]

    In mid-September, Vitality Biopharma Inc (OTCMKTS:VBIO) announced it was going to take aim at the development of an alternative to opioids as a means of treating pain. At the time, there was little doubt that the company’s cannabinoid science was capable of doing so. What wasn’t clear to VBIO shareholders was exactly how that might happen…. meaning what sort of drug might Vitality Biopharma come up with.

    We got the first of what will likely be several answers to the question today. Per today’s press release, Vitality Biopharma intends to come up with a treatment for narcotic bowel syndrome, which is a severe form of (ironically enough) opiate-induced abdominal pain.

    As a refresher, Vitality Biopharma was the name we introduced to you back on August 8th, pointing out it had developed a whole new way of making cannabinoid-based medicines. Their versions offer all the upsides of cannabinoids, but without the psychotropic (“getting high’) effects, and without some of the common downsides associated with these pharmaceuticals… like mouth and skin lesions.

    There are even bigger advantages to Vitality Biopharma’s science, however. Namely, since these drugs are prodrugs and aren’t activated until in the body, they allow for targeted delivery to the GI tract (yet can also selectively target other body parts, even as far away from the GI tract as the brain). Perhaps more than anything though, these drugs are orally-administered by virtue of being highly soluble, making them easy to use.

    It’s this nuance that makes Vitality Biopharma’s recently-announced intention so interesting, and compelling.

    Studies have found that up to 81% of patients treated with opiates have functional bowel disorders, with more than half — 58% to be exact — of opiate users reporting chronic abdominal pain stemming from the use of their prescribed painkillers. Considering 200 million opioid prescriptions are filled every year in the United States alo

  • [By Matthew Briar]

    Back in September, Vitality Biopharma Inc (OTCMKTS:VBIO) CEO Robert Brooke officially announced his company would be entering the painkiller market, specifically taking aim at the development of an alternative to opioids. His specific words? “Opiates are one of the key classes of drugs we’re seeking to replace, or to make far less necessary, as our proprietary cannabosides could provide a potent alternative form of pain relief and help avoid, or greatly reduce, the use of opiates for the treatment of many conditions…”

Best Medical Stocks To Own Right Now: Ono Pharmaceutical Co., Ltd. (OPHLF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Merck could achieve a consistent advantage versus BMS in treatment of 1L NSCLC. There is a precise crossroad that will determine the future of these two companies in this field: the question of whether or not Keytruda will be approved in May. Both the market and investors believe that it will indeed gain approval and BMS’s stock is already paying for that. In the short term, the repercussions will be the contractions in the sales of Opdivo in 2L and a bigger obstacle for Opdivo+Yervoy in 1L. But the BMS’s combo can catch up, thanks to a bigger efficacy, as I will explain in a future article. Meanwhile, a recent trial established that Merck has to pay BMS $625M plus royalties, as it infringed BMS’s intellectual property related to the use of anti-PD1 antibodies. The royalties will be 6.5% for sales between January 2017 and the end of 2023, followed by a 2.5% rate for the period from January 2024 to the end of 2026. Bristol-Myers Squibb will share the money by giving a quarter of the amount to the Japanese Ono Pharmaceutical (OTC:OPHLF), the company which had discovered Opdivo.

Top 10 High Tech Stocks To Invest In 2019

I think I might have gone too far…   Recently, I've been writing about a "secret war" in Washington, D.C. And I've been describing a very high-level source, without naming him. I'm even broadcasting a meeting with this mysterious "Metropolitan Man."   And you don't even know who he is yet.   I can understand how this probably sounds: Self-serving. Promotional. Even crazy. After all, most people haven't been reading our work for years or decades. Most subscribers don't remember when I predicted (accurately) that Fannie and Freddie would go to zero.   They didn't read my work back in 2007, long before the crisis, when I explained exactly why General Motors would go bankrupt. They never saw my famous satiric letters "from the Chairman of General Motors" where I wrote the truth about what was really happening in the heavily indebted, old carmaker.

Top 10 High Tech Stocks To Invest In 2019: HTG Molecular Diagnostics, Inc.(HTGM)

Advisors’ Opinion:

  • [By Lisa Levin] Related HTGM Mid-Afternoon Market Update: Dow Falls 50 Points; Micron Shares Jump Following Strong Earnings Report Mid-Day Market Update: ZAIS Group Gains Following Q4 Results; Xenon Pharmaceuticals Shares Decline HTG Molecular Diagnostics Completes Initial Technical Feasibility Testing with QIAGEN … (GuruFocus)
    Related Mid-Afternoon Market Update: Dow Falls 50 Points; Micron Shares Jump Following Strong Earnings Report Mid-Day Market Update: ZAIS Group Gains Following Q4 Results; Xenon Pharmaceuticals Shares Decline Zais Group reports Q4 results (Seeking Alpha)
    HTG Molecular Diagnostics Inc (NASDAQ: HTGM) shares climbed 204.1 percent to $11.95 after surging 83.64 percent on Thursday. HTG Molecular Diagnostics reported a Q4 loss of $0.76 per share on revenue of $1.5 million.
    ZAIS Group Holdings, Inc. (NASDAQ: ZAIS) shares surged 52.6 percent to $3.45. ZAIS Group reported Q4 earnings of $0.29 per share on revenue of $16.73 million.
    Global Brokerage Inc (NASDAQ: GLBR) shares jumped 24.3 percent to $2.30.
    Regulus Therapeutics Inc (NASDAQ: RGLS) shares surged 20 percent to $1.50. Regulus Therapeutics’ Chairman bought 500,000 shares at $1.22 per share.
    Rocket Fuel Inc (NASDAQ: FUEL) shares gained 15.6 percent to $5.19.
    Akoustis Technologies Inc (NASDAQ: AKTS) rose 13.3 percent to $10.75 as the company agreed to acquire wafer manufacturing facility for $2.75 million in cash.
    TOP SHIPS Inc (NASDAQ: TOPS) shares gained 12.6 percent to $1.25.
    Inventure Foods Inc (NASDAQ: SNAK) jumped 10.4 percent to $4.46 after the company announced the strategic sale of Fresh Frozen Foods for $23.7 million in cash.
    CymaBay Therapeutics Inc (NASDAQ: CBAY) surged 8.7 percent to $4.14. Cymabay Therapeutics reported a Q4 loss of $0.30 per share.
  • [By Lisa Levin] Related HTGM 20 Biggest Mid-Day Losers For Thursday 25 Stocks Moving In Thursday's Pre-Market Session HTG Molecular Diagnostics Obtains CE Mark for its HTG EdgeSeq ALKPlus Assay EU (GuruFocus)
    Related SSH 15 Biggest Mid-Day Gainers For Wednesday 12 Biggest Mid-Day Losers For Tuesday Healthcare – Top 5 Gainers / Losers as of 11:00 am (Seeking Alpha) Gainers
    HTG Molecular Diagnostics Inc (NASDAQ: HTGM) rose 63.6 percent to $3.50 in pre-market trading after the company disclosed that it has obtained CE marking in the EU for HTG EdgeSeq ALKPlus Assay.
    Sunshine Heart Inc (NASDAQ: SSH) rose 20.3 percent to $2.61 in pre-market trading after the company issued a business update regarding execution of its strategic growth plan.
    bebe stores, inc. (NASDAQ: BEBE) shares rose 11.1 percent to $4.29 in pre-market trading after the company disclosed that it is exploring strategic alternatives.
    Cancer Genetics Inc (NASDAQ: CGIX) rose 10.3 percent to $3.20 in pre-market trading after the company posted a narrower-than-expected quarterly loss.
    Five Below Inc (NASDAQ: FIVE) rose 8.8 percent to $41.50 in pre-market trading after the company reported better-than-expected earnings for its fourth quarter.
    FireEye Inc (NASDAQ: FEYE) rose 8 percent to $12.40 in pre-market trading. Goldman Sachs upgraded FireEye from Sell to Buy.
    PVH Corp (NYSE: PVH) shares rose 7.4 percent to $97.60 in pre-market trading after the company posted upbeat earnings for its fourth quarter and issued a strong earnings forecast.
    Bitauto Hldg Ltd (ADR) (NASDAQ: BITA) shares rose 7 percent to $26.00 in pre-market trading after dropping 1.30 percent on Wednesday.
    Pingtan Marine Enterprise Ltd (NASDAQ: PME) rose 6.6 percent to $4.50 in pre-market trading after gaining 0.48 pe
  • [By Lisa Levin]

    HTG Molecular Diagnostics Inc (NASDAQ: HTGM) shares shot up 175 percent to $10.80 after surging 83.64 percent on Thursday. HTG Molecular Diagnostics reported a Q4 loss of $0.76 per share on revenue of $1.5 million.

  • [By Lisa Levin]

    HTG Molecular Diagnostics Inc (NASDAQ: HTGM) shares shot up 190 percent to $11.42 after surging 83.64 percent on Thursday. HTG Molecular Diagnostics reported a Q4 loss of $0.76 per share on revenue of $1.5 million.

  • [By Lisa Levin]

    HTG Molecular Diagnostics Inc (NASDAQ: HTGM) shares were also up, gaining 136 percent to $2.95. HTG Molecular Diagnostics disclosed that its new direct-target sequencing chemistry will be launched in the first quarter.

Top 10 High Tech Stocks To Invest In 2019: Ono Pharmaceutical Co., Ltd. (OPHLF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Merck could achieve a consistent advantage versus BMS in treatment of 1L NSCLC. There is a precise crossroad that will determine the future of these two companies in this field: the question of whether or not Keytruda will be approved in May. Both the market and investors believe that it will indeed gain approval and BMS’s stock is already paying for that. In the short term, the repercussions will be the contractions in the sales of Opdivo in 2L and a bigger obstacle for Opdivo+Yervoy in 1L. But the BMS’s combo can catch up, thanks to a bigger efficacy, as I will explain in a future article. Meanwhile, a recent trial established that Merck has to pay BMS $625M plus royalties, as it infringed BMS’s intellectual property related to the use of anti-PD1 antibodies. The royalties will be 6.5% for sales between January 2017 and the end of 2023, followed by a 2.5% rate for the period from January 2024 to the end of 2026. Bristol-Myers Squibb will share the money by giving a quarter of the amount to the Japanese Ono Pharmaceutical (OTC:OPHLF), the company which had discovered Opdivo.

Top 10 High Tech Stocks To Invest In 2019: Oil States International Inc.(OIS)

Advisors’ Opinion:

  • [By Wayne Duggan]

    Instead, Genargo prefers oil services stocks with the most exposure to the U.S market. Loop names Halliburton Company (NYSE: HAL) as its top large-cap stock pick and Oil States International, Inc. (NYSE: OIS), Newpark Resources Inc (NYSE: NR) and Superior Energy Services, Inc. (NYSE: SPN) as its top small- and mid-cap stocks.

  • [By Joseph Griffin]

    Oil States International (NYSE: OIS) is one of 14 public companies in the “Oil & gas field machinery” industry, but how does it contrast to its peers? We will compare Oil States International to similar businesses based on the strength of its institutional ownership, profitability, analyst recommendations, valuation, dividends, earnings and risk.

  • [By Michael J. Carr]

    Einhorn selects investments with a traditional value approach, although he may not be as patient as a typical value investor. Einhorn took Apple (Nasdaq: AAPL) to court in an effort to force the company to return cash to shareholders, and more recently challenged Oil States International (NYSE: OIS) to unlock shareholder value.

Top 10 High Tech Stocks To Invest In 2019: Annaly Capital Management Inc(NLY)

Advisors’ Opinion:

  • [By Dan Caplinger]

    Another tax-law provision gives favorable tax status to real-estate investment trusts. REITs make investments in real estate-related assets, and they’re required to pay out almost all their income to their shareholders annually.
    Simon Property Group (SPG) is one of the biggest REITs, focusing on shopping malls and paying a 3 percent yield. But other specialty areas of the REIT universe pay much higher dividends, with REITs like Annaly Capital (NLY) that invest in mortgage-backed securities topping the list with double-digit percentage yields.

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on Salesforce.com (CRM) , Paccar (PCAR) , Cummins (CMI) , ConocoPhillips (COP) , Adobe Systems (ADBE) , Annaly Capital (NLY) and Hewlett Packard Enterprise (HPE) .

  • [By Ben Levisohn]

    Hatteras Financial (HTS) has jumped 9.4% to $15.60 after agreeing to be purchased byAnnaly Capital Management (NLY) for $1.5 billion.Annaly Capital Management has dropped 1.1% to $$10.30.

  • [By Amanda Alix]

    It was just about one year ago that QE3 made its debut, and mortgage REITs, particularly agency-only players like Annaly Capital (NYSE: NLY  ) , Armour Residential (NYSE: ARR  ) , and American Capital Agency (NASDAQ: AGNC  ) began moaning about the increased competition for mortgage-backed securities guaranteed by Fannie Mae and Freddie Mac.

  • [By Boniface Murigu]

    It’s no secret that mREITs such as American Capital Agency (NASDAQ: AGNC  ) (NASDAQ: AGNC  ) (NASDAQ: AGNC  ) , Annaly Capital Management (NYSE: NLY  ) (NYSE: NLY  ) (NYSE: NLY  ) ,and CYS Investmentshave gone through a very turbulent trading period, with all major players losing a sizable share of market value.

  • [By Amanda Alix]

    This development will likely give battered mREITs like Annaly Capital (NYSE: NLY  ) , Armour Residential (NYSE: ARR  ) , and American Capital Agency (NASDAQ: AGNC  ) a huge boost as investors begin to feel less panic regarding a tapering of the current QE3 program. Markets have responded to the Summers announcement by soaring skyward, apparently feeling relief and confidence about the fate of the taper.

Top 10 High Tech Stocks To Invest In 2019: Xenon Pharmaceuticals Inc.(XENE)

Advisors’ Opinion:

  • [By Lisa Levin]

    Xenon Pharmaceuticals Inc (NASDAQ: XENE) shares dropped 53 percent to $4.68 after the company disclosed that XEN801 did not meet efficacy endpoints in Phase 2 trial.

  • [By Jim Robertson]

    Yesterday, our Under the Radar Moversnewsletter suggested going long on small cap biopharmaceutical stock Xenon Pharmaceuticals Inc (NASDAQ: XENE):

  • [By Lisa Levin]

    Xenon Pharmaceuticals Inc (NASDAQ: XENE) shares dropped 51 percent to $4.80 after the company disclosed that XEN801 did not meet efficacy endpoints in Phase 2 trial.

  • [By Jim Robertson]

    On Monday, our Under the Radar Moversnewsletter suggestedgoing long on small cap orphan biopharmaceutical stock Xenon Pharmaceuticals (NASDAQ: XENE):

Top 10 High Tech Stocks To Invest In 2019: Vanguard Mega Cap Growth ETF (MGK)

Advisors’ Opinion:

  • [By Todd Shriber, ETF Professor]

    Three of Vanguard's mega-cap equity ETFs now sport annual expense ratios of 0.07 percent, down from 0.09 percent. Those ETFs are the Vanguard Mega Cap ETF (NYSE: MGC), Vanguard Mega Cap 300 Growth Index ETF (NYSE: MGK) and the Vanguard Mega Cap Value Index ETF (NYSE: MGV).

Top 10 High Tech Stocks To Invest In 2019: Strayer Education, Inc.(STRA)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Capella Education Company (NASDAQ: CPLA) got a boost, shooting up 32 percent to $86.60. Strayer Education Inc (NASDAQ: STRA) and Capella Education agreed to an all-stock merger. Capella Education also posted upbeat quarterly earnings.

  • [By Lisa Levin]

    In trading on Thursday, non-cyclical consumer goods & services shares fell by 1.21 percent. Meanwhile, top losers in the sector included Strayer Education Inc (NASDAQ: STRA), down 13 percent, and MGP Ingredients Inc (NASDAQ: MGPI), down 6 percent.

Top 10 High Tech Stocks To Invest In 2019: Ctrip.com International, Ltd.(CTRP)

Advisors’ Opinion:

  • [By Monica Gerson]

    Ctrip.com International, Ltd. (ADR) (NASDAQ: CTRP) is estimated to post a quarterly loss at $0.09 per share on revenue of $2.81 billion.

    Cheetah Mobile Inc (ADR) (NYSE: CMCM) is expected to report its quarterly earnings at $0.87 per share on revenue of $1.14 billion.

  • [By R. Chandrasekaran]

    The following companies are rated as Overweight:

    Tencent Holdings. Alibaba. Ctrip.com International, Ltd. (ADR) (NASDAQ: CTRP). Weibo Corp (ADR) (NASDAQ: WB). YY Inc (ADR) (NASDAQ: YY). Momo Inc (ADR) (NASDAQ: MOMO). Bitauto Hldg Ltd (ADR) (NYSE: BITA). Phoenix New Media Ltd ADR (NYSE: FENG).
    Neutral-Rated Names

    The following stocks are rated with Neutral:

  • [By Paul Ausick]

    Ctrip.com International Ltd. (Nasdaq: CTRP) traded down about 3.5% Monday and posted a new 52-week low of $42.36 after closing Friday at $43.91. The stock’s 52-week high is $60.65. Volume totaled around 4.8 million, about equal to the daily average. The company had no specific news.

  • [By Monica Gerson]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Thursday's regular session.

  • [By Brian Stoffel]

    That’s begun to change. Starting with the effective merger of Qunar with Ctrip (NASDAQ:CTRP) in 2015, the latter has become the de-facto travel site in the country. Check out the increase in revenue across the company’s business lines.

  • [By Monica Gerson]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Friday's regular session.

    Caterpillar Inc. (NYSE: CAT) Jan17 77.5 Calls Sweep: 1022 @ ASK $4.45: 1066 traded vs 2466 OI: Earnings 7/28 $75.88 Ref
    Anacor Pharmaceuticals Inc (NASDAQ: ANAC) Jan17 110 Calls: 500 @ Above Ask! $0.40: 509 traded vs 1860 OI: $99.22 Ref
    Ctrip.com International, Ltd. (ADR) (NASDAQ: CTRP) Jun16 41.25 Calls Sweep: 577 @ ASK $1.75: 649 traded vs 1927 OI: Earnings 6/15 After Close $40.54 Ref
    Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Jun16 65.0 Calls Sweep: 749 @ ASK $1.85: 813 traded vs 370 OI: $63.08 Ref
    WhiteWave Foods Co (NYSE: WWAV) Oct16 50.0 Calls: 600 @ ASK $1.60: 601 traded vs 430 OI: $45.16 Ref

    Posted-In: Unusual Put OptionsNews Options Markets

Top 10 High Tech Stocks To Invest In 2019: Navios Maritime Partners LP(NMM)

Advisors’ Opinion:

  • [By Alex McGuire]

    These are the 10 best penny stocks that have seen the biggest returns over the last week (March 7 – March 14)…

    Penny StockCurrent PriceWeekly Gain (March 7 – March 14)Ocera Therapeutics Inc. (Nasdaq: OCRX)$1.47+147.1%Internap Corp. (Nasdaq: INAP)$3.28+41.4%Soligenix Inc. (Nasdaq: SNGX)$2.94+40%Navios Maritime Partners LP (NYSE: NMM)$2.63+37%QuickLogic Corp. (Nasdaq: QUIK)$2.14+30.5%Adamis Pharmaceuticals Corp. (Nasdaq: ADMP)$4.60+22.7EXCO Resources Inc. (NYSE: XCO)$0.65+20.5%Cyclacel Pharmaceuticals Inc. (Nasdaq: CYCC)$4.38+20.3%Hebron Technology Co. Ltd. (Nasdaq: HEBT)$3.99+19.1%Curis Inc. (Nasdaq: CRIS)$2.85+18.4%

    As a reminder, this is only a tracking metric of penny stocks trading on SEC-regulated exchanges like the Nasdaq and NYSE. Although these top penny stocks are safer than those trading on the pink sheets, we don’t recommend buying any of them without the proper amount of financial research.

  • [By Elizabeth Balboa]

    Meanwhile, Safe Bulkers, Inc. (NYSE: SB) rose $0.73 throughout the 2016, Seanergy Maritime Holdings Corp. (NASDAQ: SHIP) fell $1.69 and Navios Maritime Partners L.P. (NYSE: NMM) dropped $0.93.

Top 10 High Tech Stocks To Invest In 2019: Taseko Mines Limited(TGB)

Advisors’ Opinion:

  • [By Logan Wallace]

    Taseko Mines (NYSEAMERICAN:TGB) (TSE:TKO) has earned a consensus rating of “Buy” from the seven research firms that are currently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company.

Top 10 Warren Buffett Stocks To Watch Right Now

The Kraft Heinz Co. is a $100 billion market capitalization company that generates more than $26 billion in annual revenue by selling iconic brands like Heinz Ketchup, Velveeta Cheese and Kraft Macaroni. Starting in October, Kraft Heinzs finances will be overseen by a 29-year-old.

The company announced on Friday that David Knopf will be the new chief financial officer of Kraft Heinz. Knopf has been working since 2015 at Kraft Heinz, where his responsibilities included overseeing the Planters Nuts brand and heading global budget and business planning, as well as zero-based budgeting and financial strategic planning as a vice-president.

LinkedIn

David Knopf’s LinkedIn page.

Knopf is also a partner at 3G Capital, the private equity firm backed by billionaires Jorge Paulo Lemann, Carlos Alberto Sicupira, and Marcel Herrmann Telles. 3G partnered with Warren Buffett to buy Heinz in a $23 billion deal and then merged the company with Kraft.

Top 10 Warren Buffett Stocks To Watch Right Now: Westell Technologies, Inc.(WSTL)

Advisors’ Opinion:

  • [By Jim Robertson]

    Today, our Under the Radar Moversnewsletter suggested small cap high-performance wireless infrastructure solutions stock Westell Technologies (NASDAQ: WSTL) as a buy for our short-term portfolio:

Top 10 Warren Buffett Stocks To Watch Right Now: The Herzfeld Caribbean Basin Fund, Inc.(CUBA)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    This "Trump pick" is a snub to the President’s trade and diplomatic reversals of Obama’s wins regarding Cuba. We are buying back Herzfeld Caribbean Basin Fund (CUBA), following in the footsteps of its founder, Tom Herzfeld, and his son Erik.

Top 10 Warren Buffett Stocks To Watch Right Now: Statoil ASA(STO)

Advisors’ Opinion:

  • [By Cameron Swinehart]

    Going forward I will be looking to add investments on my watchlist and trim other positions. It will be interesting to see how an overweight commodity portfolio will perform relative to the rest of the market.

     Cost Basis# SharesCurrent Price% of PortfolioCurrent ValueReturnMetal/Miners      Sprott Physical Gold Trust (PHYS)$12.4985$11.043.75%$938.40-13.13%Sprott Physical Silver Trust (PSLV)$7.95125$8.744.37%$1,092.509.04%FreePort-McMoran (FCX)$31.6731$33.874.20%$1,049.976.50%Ishares MSCI Global Gold Miners ETF (RING)$13.0695$10.644.04%$1,010.80-22.74%Energy      Statoil ASA(STO)$21.7940$22.683.63%$907.203.92%Vanguard Natural Resources LLC (VNR)$27.5636$27.874.01%$1,003.321.11%ConocoPhillips (COP)$63.6822.43$71.006.37%$1,592.5310.31%Agriculture      CVR Partner LP (UAN)$26.3630.9$18.932.34%$584.94-39.25%Adecoagro$6.78125$7.443.72%$930.008.87%Archer-Daniels Midland (ADM)$34.8030$37.244.47%$1,117.206.55%Mixed Commodity      Powershares DB Commodity Index (DBC)$26.3540$25.954.15%$1,038.00-1.54%Sprott Resource Corp$3.34400$2.714.34%$1,084.00-23.25%    Total % of portfolio49.40%               Cost Basis12,666.00      Current Value12,348.86      Return-2.50%  Source: Investing For The Future Surge In Commodity Prices

    Disclosure: I am long ADM, FCX, UAN, AGRO, RING, VNR, SCPZF.PK, COP, DBC, PHYS, PSLV. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. (More…)

  • [By Jayson Derrick]

    BP plc (ADR) (NYSE: BP), Royal Dutch Shell plc (ADR) (NYSE: RDS-A) (NYSE: RDS-B) and Statoil ASA(ADR) (NYSE: STO) are expected to outperform their peers by offering: 1) the greatest rate of change in cost reduction through technology and innovation, 2) upstream portfolios with an attractive risk to reward profile and 3) sufficient liquidity to invest in future growth.

  • [By Ben Levisohn]

    We believe that the equity market has neutralised much of its underweight energy positioning in 4Q/1Q, but was caught by the sharp rally in crude from end-January. Our base-case sees oil prices still higher by end-2016 (we see >$50/bbl), albeit with a choppy 2Q likely ahead. In this scenario a modest, rather than fully-fledged price-recovery we continue to place a lot of importance on self-help in driving ROE expansion (as opposed to relying simply on oil-leverage). Value-adjusted, we like the self-help stories around Total, Chevron, Statoil (STO), Royal Dutch Shell and Eni (E) in the group. Total is on the Citi European Focus list.

  • [By Paul Ausick]

    Norway’s Statoil ASA (NYSE: STO) announced this morning that it has acquired stakes in two North Sea projects from France’s Total S.A. (NYSE: TOT). The transaction, valued at $1.45 billion, includes a 51% equity stake in the Martin Linge field and a 40% stake in the Garantiana discovery, both located on Norway’s continental shelf.

  • [By Todd Shriber, ETF Professor]

    NORW reflects Norway's oil exposure. The ETF allocates nearly 28.8 percent of its weight to the energy, 870 basis points more than it devotes to its second-largest sector exposure, financial services. State-run Statoil ASA(ADR) (NYSE: STO) is NORW's largest individual holding at a weight of 15.3 percent, or 560 basis points more than NORW allocates to its second-largest holding.

  • [By Ben Levisohn]

    Should oil prices recover, we believe that deepwater drilling activity growth should lag growth in US shale activity, as project economics is generally better in US shales, and E&Ps involved in US shales are generally quicker to react. Deepwater activity is largely comprises a handful of companies (Petrobras (PBR), Statoil (STO), Total (TOT), Shell (RDS.A), BP (BP), ONGC, ExxonMobil (XOM) and Chevron (CVX)) and it is unlikely that these companies can meaningfully increase their rig demand in a short period of time to absorb the current oversupply. Thus, should oil prices rise in 2018, rig demand may increase, but likely not enough to tighten the market, given that supply equaling 43% of current working rig count is stacked and new supply equaling 25% of working rig count is under-construction and should be entering the market in the coming years. As a result, while we expect some improvement in rig utilization owing to rig retirements, it will unlikely be strong enough to meaningfully improve rates in 2018 above spot levels. Any demand increase in the interim could slow rig retirements materially, and be self-defeating. We thus are Sell rated on Transocean, Atwood and Noble.

Top 10 Warren Buffett Stocks To Watch Right Now: SandRidge Mississippian Trust II(SDR)

Advisors’ Opinion:

  • [By Paul Ausick]

    Sandridge Mississippian Trust II (NYSE: SDR) dropped about 18% Monday to post a new 52-week low of $0.75 after closing at $0.95 on Friday. The 52-week high is $1.79. Volume was around 1.3 million, more than nine times the daily average of around 160,000. The company had no specific news.

Top 10 Warren Buffett Stocks To Watch Right Now: Ono Pharmaceutical Co., Ltd. (OPHLF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Merck could achieve a consistent advantage versus BMS in treatment of 1L NSCLC. There is a precise crossroad that will determine the future of these two companies in this field: the question of whether or not Keytruda will be approved in May. Both the market and investors believe that it will indeed gain approval and BMS’s stock is already paying for that. In the short term, the repercussions will be the contractions in the sales of Opdivo in 2L and a bigger obstacle for Opdivo+Yervoy in 1L. But the BMS’s combo can catch up, thanks to a bigger efficacy, as I will explain in a future article. Meanwhile, a recent trial established that Merck has to pay BMS $625M plus royalties, as it infringed BMS’s intellectual property related to the use of anti-PD1 antibodies. The royalties will be 6.5% for sales between January 2017 and the end of 2023, followed by a 2.5% rate for the period from January 2024 to the end of 2026. Bristol-Myers Squibb will share the money by giving a quarter of the amount to the Japanese Ono Pharmaceutical (OTC:OPHLF), the company which had discovered Opdivo.

Top 10 Warren Buffett Stocks To Watch Right Now: Vince Holding Corp.(VNCE)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Vince Holding Corp (NYSE: VNCE) were down around 15 percent to $3.67. Vince Holding projects full-year sales and EPS to come in at or below the low end of its earlier issued outlook.

  • [By Peter Graham]

    Small cap upscale apparel brandretailer Vince Holding Corp (NYSE: VNCE) reported Q1 2017 financial results before the market opened this morning. Net sales decreased 14.2% to $58.0 million as wholesale segment sales decreased 20.9% to $35.4 million, primarily due to a reduction in full-price orders as a result of the elimination of the Companys summer delivery, and asdirect-to-consumer segment salesfell 1.0% to $22.6 million. Comparable sales decreased 5.7%, including e-commerce sales, due to a decrease in average order value.

  • [By Lisa Levin]

    Gainers

    Pyxis Tankers Inc. (NYSE: PXS) rose 47.48 percent to $$5.56, after the company announced it has entered into a definitive securities purchase agreement with a group of investors, which will result in gross proceeds of $4.8 million.
    Sigma Designs Inc (NASDAQ: SIGM) rose 22.77 percent to $6.88. Silicon Laboratories (NASDAQ: SLAB) announced plans to buy Sigma Designs for $7.05 per share in cash.
    Steadymed Ltd (NASDAQ: STDY) rose 19.35 percent to $3.70, after the company reported that no clinical trials were required for Trevyent and that the FDA had agreed to the pathway for the drug candidate's NDA resubmission.
    Iteris, Inc. (NASDAQ: ITI) rose 15.73 percent to $7.06. Earlier in the week, Zacks Investment Research had upgraded the company from "Sell" to "Hold".
    Science Applications International Corp (NYSE: SAIC) rose 13.71 percent to $85.77 as the company reported better-than-expected earnings for its third quarter.
    Technical Communications Corporation (NASDAQ: TCCO) rose 12.41 percent to $6.07, after having risen sharply in pre-marketing trading.
    Radius Health, Inc. (NASDAQ: RDUS) rose 12.41 percent to $30.81 after the company provided an update on data from the Phase 1 005 clinical study of elacestrant in patients with estrogen receptor positive breast cancer during the 2017 San Antonio Breast Cancer Symposium.
    ForeScout Technologies, Inc. (NASDAQ: FSCT) rose 12.32 percent to $25.80 after the company reported its third quarter financial results.
    Prana Biotechnology Limited (NASDAQ: PRAN) rose 11.36 percent to $3.43, as the company announced a research collaboration with Takeda Pharmaceuticals to study the ability of movement disorders compound, PBT434 to slow or prevent neurodegeneration of the gastrointestinal system.
    Catalyst Biosciences, Inc. (NASDAQ: CBIO) rose 10.49 percent to $7.90 as the company announced the appointment of Arwa Shurrab and Jamie Ellen Siegel in its clinical hemophilia

  • [By Lisa Levin]

    Shares of Vince Holding Corp (NYSE: VNCE) were down around 41 percent to $0.800. Vince Holding reported a Q4 loss of $162.1 million on revenue of $63.9 million.

Top 10 Warren Buffett Stocks To Watch Right Now: Edwards Lifesciences Corporation(EW)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Edwards Lifesciences (EW) soared to the top of the S&P 500 today after the medical-device company beat earnings and revenue forecasts, and raised its full-year guidance.

    Getty Images

    Edwards Lifesciencesgained 11% to 109.33, while the S&P 500 dipped 0.1% to 2,387.45.

    Mogran Stanley’s David Lewis andScott Wang contend that that Edwards Lifesciences is “back on track.” They explain:

    US sequential acceleration returns to the prior curve and debunks the bear case. Sequential growth in US [transcatheter aortic valve replacement, or TAVR,] in 1Q17 was ~12%, more in line with the ~13.5% average growth rate seen in the five quarters leading up to 3Q16. It’s hard to pinpoint the drivers, but we see several dynamics, including: (i) underlying device utilization thus far in 1Q, (ii) faster ramp at new hospitals where one additional TAVR per center is worth $15mn (~65% of the US upside we saw this quarter), and (iii) less acute competitive pressure from Medtronic (MDT) on larger valve sizes. SURTAVI likely played a limited role but management did not rule it out. Guidance implies a more conservative q/q US growth of ~3% for the rest of the year vs the ~12% this quarter, but underlying strength in the quarter is a material shift in US growth and intermediate penetration. As we stated in our preview, we favored the risk reward into the quarter given achievable expectations and the >20 point lag vs Intuitive YTD and would expect significant recovery tomorrow. Momentum likely continues into 2Q17 as signs of improving intermediate risk penetration provide important offsets to increased competition from Boston in early-2018 before mitral takes hold.

    Edwards Lifesciences’ market capitalization rose to $23.1 billion today from $20.9 billion yesterday.

  • [By Ben Levisohn]

    Shares of Edwards Lifesciences (EW) jumped to the top of the S&P 500 today after the medical-device maker offered its 2017 guidance this morning at its investor day.

    Getty Images

    Shares of Edwards Lifesciences gained 6.7% to $89.31 today, while the S&P 500 rose 0.2% to 2,246.19.

    Wells Fargo’sLarry Biegelsen offers his take on Edwards Lifesciences’ guidance:

    Edwards Lifesciences Corporation (EW-$83.73; Outperform) provided its 2017 outlook this morning (12/8) ahead of its investor meeting today. As expected, the company highlighted its robust pipeline which should drive strong growth for years to come. However, the company now expects Q4 16 revenue to come in at the low end of the guidance range due to currency and weakness in surgical heart valves. The 2017 guidance was generally strong on the top and bottom line, with both bracketing consensus.

    For 2017, EW expects sales of $3.0-3.4B and 10-14% underlying growth. This compares to consensus of $3.3B and 12.3% underlying growth (were at 12.6%)… For 2017 EPS, EW expects $3.30-3.45 which includes $0.10 dilution from the Valtech deal (something we highlighted in our preview) and $0.08-0.10 benefit from the accounting change for stock based compensation. Backing these two items out implies guidance of about $3.30-3.45 which compares to consensus of $3.40 and our estimate of $3.41…

    As expected, the pipeline updates were highly positive. While the initial reaction to the Q4 guidance will likely be negative, we are highly confident that the strong 2017 guidance and robust pipeline update will be the main takeaways from the meeting today.

    No negativity here: Edwards Lifesciences’ market capitalization rose to $19.1 billion today from $17.9 billion yesterday. It reported net income of $495 million on sales of $2.5 billion in 2015.

  • [By Lisa Levin]

    Breaking news

    Edwards Lifesciences Corp (NYSE: EW) announced plans to buy Valtech Cardio for $340 million in cash and stock. The company also announced a $1 billion buyback plan.
    Epizyme Inc (NASDAQ: EPZM) disclosed that it has received Fast Track designation for tazemetostat.
    Athene Holding Ltd. (NYSE: ATH) reported that it has priced its 23.8 million share IPO between $38 per share and $42 per share.
    Lannett Company, Inc. (NYSE: LCI) reported the approval for its Metaxalone Tablets USP, 800 mg.

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Wednesday was Edwards Lifesciences Corp. (NYSE: EW) which jumped about 10% to $108.91. The stocks 52-week range is $81.12 to $1221.75. Volume was roughly 7.3million which is above the daily average of around 2.2 million shares.

Top 10 Warren Buffett Stocks To Watch Right Now: Zumiez Inc.(ZUMZ)

Advisors’ Opinion:

  • [By Chris Lange]

    Zumiez Inc. (NASDAQ: ZUMZ) is set to report its fiscal second-quarter results on Thursday. The consensus estimates predicta net loss of $0.08 per share and $177.35 million in revenue. Shares were changing hands at $16.61 on Fridays close. The consensus price target is $15.20, and the stock has a 52-week range of $11.53 to $23.45.

  • [By Lisa Levin]

    Zumiez Inc. (NASDAQ: ZUMZ) was down, falling around 10 percent to $19.78. Zumiez reported in-line earnings for its third quarter on Thursday.

    Commodities

  • [By Lisa Levin]

    Zumiez Inc. (NASDAQ: ZUMZ) was down, falling around 12 percent to $19.15. Zumiez reported in-line earnings for its third quarter on Thursday.

    Commodities

  • [By Dan Caplinger]

    Friday was a good day on Wall Street, as the stock market responded favorably to encouraging news on the employment front. The U.S. unemployment rate dropped on fairly strong job creation during the month of February, and that helped push the Dow, S&P 500, and Nasdaq Composite to modest gains of roughly between a quarter percent and a half percent. Yet even with a positive mood among market participants, some stocks weren’t able to participate in the end-of-week rally. Finisar (NASDAQ:FNSR), Zumiez (NASDAQ:ZUMZ), and Winnebago Industries (NYSE:WGO) were among the worst performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so poorly.

Top 10 Warren Buffett Stocks To Watch Right Now: Arch Coal, Inc. (ARCH)

Advisors’ Opinion:

  • [By Ben Levisohn]

    The VanEck Vectors Coal ETF has gained 1.1% to $12.28 at 2:01 p.m. today, while Arch Coal (ARCH), which resumed listed trading yesterday after emerging from bankruptcy, has fallen 3% to $62.98.

Top 10 Warren Buffett Stocks To Watch Right Now: Daktronics, Inc.(DAKT)

Advisors’ Opinion:

  • [By Monica Gerson]

    Daktronics, Inc. (NASDAQ: DAKT) is projected to report its quarterly earnings at $0.08 per share on revenue of $156.17 million.

    Guidewire Software Inc (NYSE: GWRE) is estimated to post its quarterly earnings at $0.06 per share on revenue of $92.43 million.

  • [By Monica Gerson]

    Daktronics, Inc. (NASDAQ: DAKT) is estimated to report its quarterly earnings at $0.08 per share on revenue of $156.17 million. Daktronics shares slipped 0.13 percent to close at $7.97 on Tuesday.

stock market analysis software

A high dividend yield can be the ultimate retirement holding. Or it can be a trap.

Today, I’m going to show you five stocks with mouth-watering yields of between 6% and 23% that are tomorrow’s dividend disasters. If you own shares in any of these firms, sell them now.

stock market analysis software: HCI Group, Inc.(HCI)

Advisors’ Opinion:

  • [By Jim Robertson]

    Small cap Florida insurance stock HCI Group Inc (NYSE: HCI) has taken a hit with shares down around 21% over the past week on predictions that Hurricane Irma would hit Florida albeit sharesrose 2.74%on Friday when it became clear that it would not be as catastrophic as feared:

stock market analysis software: Internationa Flavors & Fragrances, Inc.(IFF)

Advisors’ Opinion:

  • [By Lee Jackson]

    International Flavors & Fragrances Inc. (NYSE: IFF) is yet another company that hit our screens witha 10% institutional owner buying stock twice last week. Winder Investment purchased a total of 70,000 shares. At $128.38per share, the total for the trade was a solid $9 million. Later in the week the company stepped in again and bought another100,000 shares at prices between $129.47 and 132.20 apiece. The total for that buy was posted at $13 million. The shares closed trading last Friday at $133.19, so some timely buys for sure. The 52-week trading range is $112.91 to $143.64. The consensus price target is $131.40.

stock market analysis software: Allscripts Healthcare Solutions, Inc.(MDRX)

Advisors’ Opinion:

  • [By Benzinga News Desk]

    Goldman Sachs (NYSE: GS) has at least one billion reasons to hope President Trump’s paring back of Dodd-Frank will include the Volcker Rule: Link

    ECONOMIC DATA
    10:30 a.m. Dallas Fed Manufacturing Business Index
    11:30 a.m. 6-Month Bill Auction
    11:30 a.m. 3-Month Bill Auction
    1 p.m. 2-Year Note Auction
    1:15 p.m. Chicago Fed President Evans Speaks
    6:30 p.m. FOMC Member Kaplan Speaks
    ANALYST RATINGS
    Piper Jaffray upgraded Best Buy Co (NYSE: BBY) from Neutral to Overweight
    Wells Fargo upgraded Allscripts Healthcare (NASDAQ: MDRX) from Market Perform to Outperform
    Mizuho upgraded Universal Health Service (NYSE: UHS) from Neutral to Buy
    Piper Jaffray downgraded The Michaels Companies (NASDAQ: MIK) from Overweight to Neutral
    JMP Securities downgraded KB Home (NYSE: KBH) from Market Outperform to Market Perform
    Raymond James downgraded Sierra Wireless Inc. (NASDAQ: SWIR) from Outperform to Market Perform

    This is a tool used by the Benzinga News Desk each trading day — it's a look at everything happening in the market, in five minutes. To get the full version of this note every morning, click here or email minutes@benzinga.com.

  • [By Monica Gerson]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Friday's regular session.

    Texas Instruments Incorporated (NASDAQ: TXN) Fri 7/1 62.0 Puts (Wkly) Sweep: 1426 @ ASK $1.24: 1426 traded vs 0 OI: Earnings 7/27 $61.86 Ref
    Allscripts Healthcare Solutions Inc (NASDAQ: MDRX) Jul16 13.0 Puts Sweep: 500 @ ASK $0.45: 500 traded vs 0 OI: Earnings 8/2 $13.07 Ref
    Intel Corporation (NASDAQ: INTC) Jul16 30.0 Puts: 7500 @ ASK $0.26: 7658 traded vs 47k OI: Earnings 7/20 $32.07 Ref
    Ares Capital Corporation (NASDAQ: ARCC) Dec16 16.0 Puts Sweep: 963 @ ASK $2.75: 974 traded vs 18 OI: Earnings 8/2 $14.45 Ref
    LinkedIn Corp (NYSE: LNKD) Aug16 115 Puts: 600 @ ASK $4.05: 615 traded vs 386 OI: $132.12 Ref

    Posted-In: Unusual Put OptionsNews Options Markets

stock market analysis software: American Software, Inc.(AMSWA)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of American Software, Inc. (NASDAQ: AMSWA) were down 12 percent to $10.58. American Software reported preliminary Q4 adjusted earnings of $0.09 per share on revenue of $26.3 million.

stock market analysis software: Smith & Nephew SNATS, Inc.(SNN)

Advisors’ Opinion:

  • [By Charles Carlson, CEO and Portfolio Manager, Horizon Investment Services]

    For investors looking for growth but also income, I especially like three health-care related stocksFresenius Medical (FMS), Novo Nordisk (NVO), and Smith & Nephew (SNN).

stock market analysis software: Ono Pharmaceutical Co., Ltd. (OPHLF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Merck could achieve a consistent advantage versus BMS in treatment of 1L NSCLC. There is a precise crossroad that will determine the future of these two companies in this field: the question of whether or not Keytruda will be approved in May. Both the market and investors believe that it will indeed gain approval and BMS’s stock is already paying for that. In the short term, the repercussions will be the contractions in the sales of Opdivo in 2L and a bigger obstacle for Opdivo+Yervoy in 1L. But the BMS’s combo can catch up, thanks to a bigger efficacy, as I will explain in a future article. Meanwhile, a recent trial established that Merck has to pay BMS $625M plus royalties, as it infringed BMS’s intellectual property related to the use of anti-PD1 antibodies. The royalties will be 6.5% for sales between January 2017 and the end of 2023, followed by a 2.5% rate for the period from January 2024 to the end of 2026. Bristol-Myers Squibb will share the money by giving a quarter of the amount to the Japanese Ono Pharmaceutical (OTC:OPHLF), the company which had discovered Opdivo.

Best Heal Care Stocks For 2018

Department-store chain Sears Holdings is seeking to stem itsbleedingby closing another 150 stores, including 108 Kmart locations, and selling its Craftsman brand to raise cash.

The ailing retailer said Thursday that it had reached a deal to sell the tools brand to Stanley Black & Decker for a net present value of about $900 million, including future royalty payments.

The move came several months after Sears put the Craftsman, Kenmore and DieHard brands up for sale as it seeks an elusive turnaround.

The company said late Wednesdaythat it would close 108 Kmart stores and 42 Sears stores, calling it “adifficult but necessary step as we take actions to strengthen the companys operations and fund its transformation.”

.oembed-asset-link { border-bottom: 1px solid #e1e1e1; } .oembed-link-anchor { display: block; clear: both; } .oembed-link-thumbnail{ float: left; padding: 14px; } .oembed-link-thumbnail img { max-width: 78px; max-height: 60px; display: block; } p.oembed-link-title { font-size: 75%; color: #009BFF; margin: 0 14px; padding-top: 12px; font-weight:normal; text-align: left; line-height: 120%; } p.oembed-link-desc { font-size: 100%; color: #666; font-weight: normal; margin: 0 14px 14px 14px; font-family: ‘Futura Today Light’; text-align: left; line-height: 120%; }

USA TODAY

Best Heal Care Stocks For 2018: Ono Pharmaceutical Co., Ltd. (OPHLF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Merck could achieve a consistent advantage versus BMS in treatment of 1L NSCLC. There is a precise crossroad that will determine the future of these two companies in this field: the question of whether or not Keytruda will be approved in May. Both the market and investors believe that it will indeed gain approval and BMS’s stock is already paying for that. In the short term, the repercussions will be the contractions in the sales of Opdivo in 2L and a bigger obstacle for Opdivo+Yervoy in 1L. But the BMS’s combo can catch up, thanks to a bigger efficacy, as I will explain in a future article. Meanwhile, a recent trial established that Merck has to pay BMS $625M plus royalties, as it infringed BMS’s intellectual property related to the use of anti-PD1 antibodies. The royalties will be 6.5% for sales between January 2017 and the end of 2023, followed by a 2.5% rate for the period from January 2024 to the end of 2026. Bristol-Myers Squibb will share the money by giving a quarter of the amount to the Japanese Ono Pharmaceutical (OTC:OPHLF), the company which had discovered Opdivo.

Best Heal Care Stocks For 2018: Autohome Inc.(ATHM)

Advisors’ Opinion:

  • [By R. Chandrasekaran]

    The following stocks are rated with Neutral:

    JD.Com Inc(ADR) (NASDAQ: JD). Vipshop Holdings Ltd – ADR (NYSE: VIPS). Autohome Inc (ADR) (NYSE: ATHM). SouFun Holdings Ltd (NYSE: SFUN). Leju Holdings Ltd (ADR) (NYSE: LEJU).
    Underweight Names

    The following stocks are rated Underweight:

  • [By Monica Gerson]

    Autohome Inc (ADR) (NYSE: ATHM) is estimated to report its quarterly earnings at $1.68 per share on revenue of $1.05 billion.

    Vera Bradley, Inc. (NASDAQ: VRA) is expected to report its quarterly earnings at $0.05 per share on revenue of $106.75 million.

Best Heal Care Stocks For 2018: CIRCOR International, Inc.(CIR)

Advisors’ Opinion:

  • [By Lisa Levin]

    CIRCOR International, Inc. (NYSE: CIR) was down, falling around 15 percent to $60.91. CIRCOR reported Q4 adjusted earnings of $0.48 per share on revenue of $158 million. Stifel Nicolaus downgraded Circor from Buy to Hold.